Here is Imugene’s latest update on anti-cancer therapies HER-Vaxx & CF33

Be the First to Comment Read
Sponsored

Here is Imugene’s latest update on anti-cancer therapies HER-Vaxx & CF33

 Here is Imugene’s latest update on anti-cancer therapies HER-Vaxx & CF33

Summary

  • Imugene Limited (ASX:IMU) recently presented encouraging data on the Company’s products at the 2021 AACR Annual Meeting.
  • City of Hope’s Dr Yanghee Woo shared a presentation on Imugene’s CF33 oncolytic virus program.
  • Chief Medical Officer Dr Rita Laeufle expanded on interim analysis data, previously presented on HER-Vaxx cancer immunotherapy in 2020.

In the latest update, Imugene Limited (ASX:IMU) informed that City of Hope’s Dr Yanghee Woo and the Company’s Chief Medical Officer Dr Rita Laeufle delivered presentations on its products at the 2021 Annual Meeting of AACR (American Association for Cancer Research).

Dr Woo shared important pre-clinical data on Imugene’s lead oncolytic virus at the prestigious Annual Meeting, whereas Dr Laeufle presented interim analysis data on the HER-2 cancer immunotherapy.

Related Read: Imugene to Deliver Presentations on HER-Vaxx and CF33 at AACR Annual Meeting 2021

Key Elements of Dr Woo’s Presentation

The abstract presentation by City of Hope’s Dr Yanghee Woo was focused on Imugene’s CF33 oncolytic virus program.

Dr Woo’s team engineered a unique chimeric orthopoxvirus, CF33-hNIS-antiPDL1, which demonstrates strong preclinical activity against several solid tumours. Besides, it shows an inherent robust anti-cancer activity against PDAC (pancreatic ductal adenocarcinoma).

Her team examined the CF33-hNIS-antiPDL1 virus for its ability to track and destroy distant peritoneal metastases following local in vivo administration of the virus. The investigation revealed that the subcutaneous intratumoral delivery of this novel chimeric immuno-oncolytic virus reduces burden of peritoneal tumour, along with increasing survival in a PDAC mouse model.

Besides, the presentation showed that 124I-based PET/CT scan can be utilised to visualise peritoneal and SC tumours treated with the Company’s CF33-hNIS-antiPDL1.

Fundamental Details of Dr Laeufle’s Presentation

In the AACR Annual Meeting, Dr Laeufle expanded on interim analysis data, previously presented on HER-Vaxx cancer immunotherapy in 2020. She highlighted the following data in her presentation:

  • Treatment with HER-Vaxx clearly shows that all patients develop high levels of HER2-specific antibodies initially in the treatment protocol.
  • Evaluation of the antibody data demonstrates that high levels of HER2-specific antibodies are maintained during the stages of treatment and maintenance. Besides, it reveals that only minimal booster injections of Imugene’s HER-Vaxx are needed to sustain the high levels.
  • High and constant HER2 antibody levels correlate with the early separation of the KM (Kaplan Meier) Curves for progression free survival (PFS) and overall survival (OS) clinical trial endpoints.
  • The interim data suggests that the treatment is well tolerated and effective, with an overall survival benefit which is superior to standard-of-care chemotherapy alone.

The recruitment of patients under Phase 2 trial of HER-Vaxx has already been completed in January 2021. The Company now expects to read out the correlation of antibodies with tumour response, final tumour response, and final PFS and OS data in this year.

As at 2:41 AM AEST, Imugene shares are trading at AUD 0.162.

Good Read: Imugene Limited’s (ASX:IMU) HER-Vaxx Delivers Promising Results in Phase 2 Interim Analysis

Disclaimer

Speak your Mind

Featured Articles

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK